We’re improving the lives of patients with rare cancers.
Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer.
Hillstream's competitive advantage is to enhance the safety and efficacy of oncology therapies by encapsulating them in polymeric injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek FDA Orphan Designation in specific indications.
Hillstream's formulations of tumor necrosis factor-alpha, salinomycin, bortezomib, and paclitaxel are currently in preclinical development for cancers with significant unmet need. By taking advantage of the FDA's 505(b)(2) regulatory pathway for bortezomib and paclitaxel, the Company could expedite the development process and bring these novel formulations to market to offer patients hope.
Hillstream BioPharma looks forward to pre-IND discussion with FDA in Q4
Hillstream BioPharma CEO Randy Milby sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco.
Hillsteam BioPharma is developing targeted cancer therapeutics designed to be safer and more efficacious than currently available chemo-therapies.
Tumor necrosis factor-alpha (TNF-alpha) for targeted delivery of DNA into tumor with high specificity and low toxicity.
First-in-class, highly potent, small molecule cancer stem cell (CSC) inhibitor encapsulated in a nanoparticle for targeted delivery to tumors.
Nanoparticle formulation of FDA-approved bortezomib for the treatment of multiple myeloma, a rare cancer with significant unmet need.